Compare CXH & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CXH | IFRX |
|---|---|---|
| Founded | 1989 | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.0M | 71.1M |
| IPO Year | N/A | 2017 |
| Metric | CXH | IFRX |
|---|---|---|
| Price | $7.95 | $1.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 25.9K | ★ 650.6K |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 3.56% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | N/A | ★ $73,729.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,054.36 |
| P/E Ratio | $33.35 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.41 | $0.71 |
| 52 Week High | $7.74 | $2.77 |
| Indicator | CXH | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 53.90 | 55.81 |
| Support Level | $7.87 | $0.99 |
| Resistance Level | $8.01 | $1.16 |
| Average True Range (ATR) | 0.08 | 0.08 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 75.00 | 97.37 |
Mfs Investment Grade Municipal Trust is a United States-based diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax, but may also consider capital appreciation. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowing for investment purposes, in tax-exempt bonds and tax-exempt notes.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.